resectable hepatocellular carcinoma
Showing 1 - 11 of 11
Resectable Hepatocellular Carcinoma Trial in Jakarta Pusat (Liver Resection)
Completed
- Resectable Hepatocellular Carcinoma
- Liver Resection
-
Jakarta Pusat, DKI Jakarta, IndonesiaDr. Cipto Mangunkusumo General Hospital
Aug 24, 2023
Resectable Hepatocellular Carcinoma Trial (Tislelizumab, Tislelizumab, Lenvatinib)
Not yet recruiting
- Resectable Hepatocellular Carcinoma
- Tislelizumab
- Tislelizumab, Lenvatinib
- (no location specified)
Mar 29, 2023
Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer Trial in Boston (Durvalumab, Tremelimumab,
Not yet recruiting
- Resectable Hepatocellular Carcinoma
- +2 more
- Durvalumab
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Jan 18, 2023
Plasma DNA Methylation in Peripheral Blood From Resectable Liver
Recruiting
- Resectable Hepatocellular Carcinoma
- Biospecimen Collection
- Electronic Health Record Review
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 6, 2023
Resectable Hepatocellular Carcinoma Trial (Cadonilimab, TACE, Surgery)
Not yet recruiting
- Resectable Hepatocellular Carcinoma
- Cadonilimab
- +2 more
- (no location specified)
Dec 12, 2022
Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8 Trial
Recruiting
- Resectable Hepatocellular Carcinoma
- +4 more
- Atezolizumab
- +2 more
-
Houston, Texas
- +1 more
Oct 12, 2022
Resectable Hepatocellular Carcinoma Trial in Houston (Nivolumab, Pegargiminase, Resection)
Recruiting
- Resectable Hepatocellular Carcinoma
- Nivolumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 10, 2022
Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma Trial in Boston (Atezolizumab, Bevacizumab, Stereotactic Beam
Recruiting
- Hepatocellular Carcinoma
- Resectable Hepatocellular Carcinoma
- Atezolizumab
- +2 more
-
Boston, MassachusettsMassachusetts General Hospital Cancer Center
Feb 10, 2022
Resectable Hepatocellular Carcinoma Trial in Tianjin (Camrelizumab:200mg, iv,d1 q2w;apatinib:250mg,po,qd,q2w)
Recruiting
- Resectable Hepatocellular Carcinoma
- Camrelizumab:200mg, iv,d1 q2w;apatinib:250mg,po,qd,q2w
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Insititute and Hospital
Nov 3, 2021
Resectable Hepatocellular Carcinoma Trial in Tianjin (Tislelizumab combined with Lenvatinib)
Not yet recruiting
- Resectable Hepatocellular Carcinoma
- Tislelizumab combined with Lenvatinib
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Insititute and Hospital
Apr 6, 2021
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma Trial in Buffalo (biological, other, drug)
Completed
- Anaplastic Astrocytoma
- +64 more
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401
- +3 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Oct 3, 2016